pensation, as a means to evaluate period-to-period
comparisons, as well as comparisons to our competitors' operating results.
Management also uses this information internally for forecasting and
budgeting, as it believes that the measures are indicative of Thoratec core
operating results. Management also believes that non-GAAP financial
measures provide useful supplemental information to management and
investors regarding the performance of the company's business operations,
provide a greater transparency with respect to key metrics used by
management in its decision making, facilitate comparisons of results for
current periods and guidance for future periods with our historical
operating results, and assist in analyzing future trends.
Non-GAAP net income (loss) consists of GAAP net income (loss) before
taxes, excluding, as applicable, share-based compensation expense under
SFAS No. 123R, amortization of purchased intangibles, and the 2007 changes
in the value of the make-whole provision of our convertible notes, each as
adjusted by the amount of additional taxes payable or tax benefit that the
company would accrue if it used non-GAAP results instead of GAAP results to
calculate the company's tax liability.
Non-GAAP EPS is defined as non-GAAP net income divided by the weighted
average number of shares on a fully-diluted basis.
Non-GAAP gross profit and gross margin consist of GAAP gross profit and
gross margin excluding share-based compensation expense under SFAS No.
Non-GAAP operating expenses consist of GAAP operating expenses
excluding share-based compensation expense under SFAS No. 123R and
amortization of purchased intangibles
Non-GAAP tax rate consists of the GAAP tax rate adjusted for the tax
effect of the adjustments from GAAP net income to non-GAAP net income.
Management believes that it is useful in measuring Thoratec's
operations to exclude amortization of intangibles. These costs are
primarily fixed at the Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Related biology technology :1
. Thoratec Schedules Third Quarter 2008 Conference Call, Webcast2
. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History3
. Thoratec Presentation at JP Morgan Conference to be Webcast4
. Thoratec Announces Appointment of Steven H. Collis to Board of Directors5
. Thoratec Presentation at Bear Stearns Conference To Be Webcast6
. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel7
. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results8
. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results9
. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 200810
. Vanda Pharmaceuticals Reports Third Quarter 2008 Results11
. United Therapeutics Reports Third Quarter 2008 Financial Results